New antibody drug aims to outsmart tumors by targeting two immune pathways

NCT ID NCT07623707

Not yet recruiting Disease control Sponsor: FutureGen Biopharmaceutical (Beijing) Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called FG-B901, a bispecific antibody that targets two immune proteins (PD-L1 and CD40) to activate the immune system against tumors while reducing side effects. It is given alone or with chemotherapy to 264 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FG-B901 (a bispecific antibody targeting PD-L1 and CD40)
What this could lead to: If successful, this could lead to a new treatment option for advanced solid tumors that are resistant to standard therapies.
What could go wrong: This is an early phase I/II trial, so safety and effectiveness are not yet proven. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Fudan University Shanghai Cancer Center

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.